Papers

3

Total Citations

18

H-Index

3

About

Marc-Oliver Grimm is a leading urologic surgeon and clinical researcher whose work centers on advancing surgical outcomes for kidney and prostate cancers. He is best known for his pivotal role in the OpeRa trial, a landmark randomized controlled trial comparing open versus robotic-assisted partial nephrectomy in patients with intermediate- to high-complexity kidney tumors. This study, published in 2025 and already garnering 12 citations, provides critical Level 1 evidence on postoperative complications and has significant implications for surgical decision-making. Grimm has also made important contributions to prostate cancer care, investigating risk factors for vesicourethral anastomotic strictures following robotic-assisted radical prostatectomy, particularly in patients who have undergone radiotherapy. His research further explores how patient-specific factors—such as body mass index and prior abdominal surgeries—affect the technical steps and outcomes of robot-assisted radical prostatectomy. By combining rigorous trial methodology with a focus on real-world surgical challenges, Grimm’s work directly informs clinical practice and improves patient safety. His growing citation record reflects the high impact of his contributions to evidence-based urologic oncology.

Research Focus

Key Achievements

3
H-Index
3
Papers
18
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa
12 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Jena University Hospital, Comprehensive Cancer Center Mainfranken

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago